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Objectives The aim of this post hoc analysis from the TNT (Treating to New Targets) trial is to determine whether patients
with previous coronary artery bypass grafting (CABG) surgery achieved clinical benefit from intensive low-density
lipoprotein (LDL)-cholesterol lowering.
Background The development and progression of atherosclerosis is accelerated in coronary venous bypass grafts.
Methods A total of 10,001 patients with documented coronary disease, including 4,654 with previous CABG, were ran-
domized to atorvastatin 80 or 10 mg/day and were followed for a median of 4.9 years. The primary end point
was the occurrence of a first major cardiovascular event (cardiac death, nonfatal myocardial infarction, resusci-
tated cardiac arrest, or stroke).
Results A first major cardiovascular event occurred in 11.4% of the patients with prior CABG and 8.5% of those without
prior CABG (p  0.001). In CABG patients, mean LDL-cholesterol levels at study end were 79 mg/dl in the
80-mg arm and 101 mg/dl in the 10-mg arm, and the primary event rate was 9.7% in the 80-mg arm and
13.0% in the 10-mg arm (hazard ratio 0.73, 95% confidence interval 0.62 to 0.87, p  0.0004). Repeat revas-
cularization during follow-up, either CABG or percutaneous coronary intervention, was performed in 11.3% of the
CABG patients in the 80-mg arm and 15.9% in the 10-mg arm (hazard ratio 0.70, 95% confidence interval 0.60
to 0.82, p  0.0001).
Conclusions Intensive LDL-cholesterol lowering to a mean of 79 mg/dl with atorvastatin 80 mg/day in patients with previous
CABG reduces major cardiovascular events by 27% and the need for repeat coronary revascularization by 30%, com-
pared with less intensive cholesterol-lowering to a mean of 101 mg/dl with atorvastatin 10 mg/day. (A Study to De-
termine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels [TNT];
NCT00327691) (J Am Coll Cardiol 2008;51:1938–43) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.12.054S
a
a
a
h
S
A
a
P
c
S
B
A
foronary artery bypass graft surgery (CABG) is a major
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May 20, 2008:1938–43 High-Dose Atorvastatin in Coronary Bypass Patientsclerosis continues to progress in native coronary arteries. In
act, atherosclerosis of native coronary and saphenous vein
rafts (SVG) is accelerated, and low-density lipoprotein
LDL) cholesterol is an important causative factor (3). The
ccelerated atherosclerosis in these patients results in recur-
ent angina in 15% and ischemic events in 10% at 5 years
fter CABG (1).
On the basis of the findings of several recent studies,
ncluding the TNT (Treating to New Targets) study,
ggressive lowering of LDL-cholesterol to 70 to 80 mg/dl
r lower in coronary patients decreases major cardiovascular
vents (4–6). However, the role of aggressive lipid-lowering
n patients with CABG is less clear. Prior trials (7–10) have
ound that lipid-lowering after CABG decreases angio-
raphic progression of native coronary and SVG atheroscle-
osis and might decrease major cardiovascular outcomes.
owever, in all these randomized trials, LDL cholesterol in
he treatment groups was reduced to no lower than 90 to
00 mg/dl.
We hypothesized that aggressive lipid-lowering with
torvastatin 80 mg to achieve LDL cholesterol of 80 mg/dl
ould reduce major cardiovascular events in CABG pa-
ients, compared with conventional lipid-lowering therapy.
he TNT study was ideal for testing this hypothesis,
ecause 4,654 patients with prior CABG were randomized
o high- or low-dose atorvastatin.
ethods
tudy design and patients. The design of the TNT study
as been described in detail previously (4,11). All patients
ave written informed consent, and the study was approved
y the research ethics committee or institutional review
oard at each participating center. Eligible participants were
en and women ages 35 to 75 years who had clinically
vident coronary heart disease (CHD), defined as previous
yocardial infarction, previous or current angina with
bjective evidence of atherosclerotic CHD, or a history of
oronary revascularization. A history of CABG was deter-
ined by patient self-report. The most important exclusion
riteria were hypersensitivity to statins, active liver disease,
ephrotic syndrome, uncontrolled diabetes or hypertension,
coronary event or revascularization within 1 month, an
jection fraction 30%, significant valvular disease, and
onskin cancer or another survival-limiting disease.
Eligible patients with LDL cholesterol levels above 130
g/dl off treatment underwent an 8-week run-in period of
pen-label treatment with 10 mg of atorvastatin daily. At
he end of the run-in phase, participants with LDL 130
g/dl were randomized in a double-blind fashion to 80 mg
r 10 mg of atorvastatin daily. Patients were followed for a
edian of 4.9 years.
tatistical analyses. The primary outcome was the occur-
ence of a major cardiovascular event, defined as death from
HD, nonfatal nonprocedure-related myocardial infarc-ion, resuscitated cardiac arrest, or stroke (fatal or nonfatal). loronary revascularization was a
omponent of a secondary end
oint.
Differences in baseline charac-
eristics in participants with and
ithout prior CABG were deter-
ined with t tests for continuous
ariables and chi-squared tests
or dichotomous variables. We
sed the same tests to compare
ABG patients in the 80- and
0-mg groups.
All analyses were performed
n an intention-to-treat basis.
ll randomized patients who were dispensed 1 dose of the
tudy drug were included in the analyses. The primary and
econdary composite end points were analyzed from the
ime of first dose of study drug to the first event, according
o the Kaplan-Meier method. We calculated the frequency
f the primary and secondary efficacy outcomes and corre-
ponding hazard ratios (HRs) (unadjusted) during our
nalysis of differences between post-CABG and non-
ABG patients. We repeated this analysis in the subset of
ost-CABG patients, comparing high-dose and low-dose
torvastatin treatment groups.
aseline Characteristicsf Patients by History of CABG Surgery
Table 1 Baseline Characteristicsof Patients by History of CABG Surgery
Prior CABG
(n  4,654)
No Prior CABG
(n  5,347) p Value
Age, yrs 62.8 8.2 59.5 9.1 0.0001
Male (%) 3,881 (83.4%) 4,218 (78.9%) 0.0001
White (%) 4,389 (94.3%) 5,021 (93.9%) 0.394
Body mass index, kg/m2 28.5 4.6 28.5 4.6 0.822
Cardiovascular risk
factors (%)
Current smoker 426 (9.2%) 915 (17.1%) 0.0001
Hypertension 2,696 (57.9%) 2,716 (50.8%) 0.0001
Diabetes mellitus 823 (17.7%) 678 (12.7%) 0.0001
Cardiovascular history (%)
Angina 3,924 (84.3%) 4,226 (79.0%) 0.0001
Myocardial infarction 2,450 (52.6%) 3,383 (63.3%) 0.0001
Cerebrovascular
accident
309 (6.6%) 208 (3.9%) 0.0001
Peripheral-arterial
disease
727 (15.6%) 446 (8.3%) 0.0001
Percutaneous coronary
intervention
1,456 (31.3%) 3,951 (73.9%) 0.0001
Lipids (mg/dl)*
LDL cholesterol 98 17 97 18 0.101
Total cholesterol 175 24 174 24 0.183
Triglycerides 154 73 148 69 0.0001
HDL cholesterol 47 11 48 11 0.0001
Lipid values at the end of the 8-week run-in period on atorvastatin 10 mg/day.
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft surgery
CHD  coronary heart
disease
CI  confidence interval
HR  hazard ratio
LDL  low-density
lipoprotein
SVG  saphenous vein
graftCABG  coronary artery bypass grafting surgery; HD
ow-density lipoprotein.L  high-density lipoprotein; LDL 
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High-Dose Atorvastatin in Coronary Bypass Patients May 20, 2008:1938–43esults
atient characteristics. Of the 10,001 total TNT partici-
ants, 4,654 (47%) had a history of CABG. Compared with
articipants without a history of CABG, those with CABG
ere older, more likely male, and were more likely to have
history of diabetes mellitus, cerebrovascular accident, and
eripheral arterial disease, as shown in Table 1.
Of the 4,654 patients with prior CABG, 2,316 were
andomized to atorvastatin 80 mg/day and 2,338 were ran-
omized to atorvastatin 10 mg/day. As shown in Table 2, the
linical features of the CABG patients in the 80- and
0-mg groups were similar. The mean interval between
ABG and study screening was 3.9  4.3 years in the
0-mg group and 4.0  4.4 years in the 10-mg group.
hanges in lipid levels in CABG patients. In the ator-
astatin 80-mg group, LDL-cholesterol was reduced from
63 mg/dl in samples collected before the 8-week run-in
eriod to 79 mg/dl at study end, a 51% reduction. In the
0-mg group, LDL-cholesterol was reduced from 163 mg/dl
efore treatment to 101 mg/dl at study end, a 38% reduction.
riglyceride levels were reduced by 34% among patients
eceiving atorvastatin 80 mg and by 23% among patients
eceiving 10 mg. The high-density lipoprotein cholesterol
evels were similar in the 80- and 10-mg groups during
reatment.
vents during follow-up. A first major cardiovascular
vent (CHD death, myocardial infarction, resuscitated car-
iac arrest, or stroke) occurred in 529 CABG patients
11.4%) and in 453 patients (8.5%) without prior CABG
HR 1.38, 95% confidence interval [CI] 1.22 to 1.56; p 
Baseline Characteristics by Treatment Group Am
Table 2 Baseline Characteristics by Treatm
Atorvast
(n 
Age, yrs 62.8
Male, n (%) 1,941
White, n (%) 2,197
Body mass index, kg/m2 28.6
Cardiovascular risk factors, n (%)
Current smoker 221
Hypertension 1,377
Diabetes mellitus 420
Cardiovascular history, n (%)
Angina 1,969
Myocardial infarction 1,201
Cerebrovascular accident 155
Peripheral-arterial disease 346
Percutaneous coronary intervention 739
Lipids (mg/dl)*
LDL cholesterol 98
Total cholesterol 175
Triglycerides 154
HDL cholesterol 47
*Lipid values at the end of the 8-week run-in period on atorvastatin 1
Abbreviations as in Table 1..0001) as depicted in Figure 1. Other end point eventsere also more common in patients with previous CABG,
s shown in Table 3.
Among post-CABG patients, a primary end-point event
ccurred in 224 patients (9.7%) in the 80-mg atorvastatin
roup compared with 305 patients (13.0%) in the 10-mg
roup, a 27% relative risk reduction and a 3.3% absolute risk
eduction (HR 0.73, 95% CI 0.62 to 0.87, p 0.0004). The
aplan-Meier curves for the primary outcome for the 80-
nd 10-mg groups of CABG patients are illustrated in
igure 2. During follow-up, 262 patients (11.3%) in the
Figure 1 Kaplan-Meier Curves for a Primary End-Point
Event in Patients With and Without Prior CABG
Primary end points were cardiac death, myocardial infarction, resuscitated car-
diac arrest, and stroke. CABG  coronary artery bypass graft surgery; CI 
confidence interval; HR  hazard ratio.
Patients With CABG
roup Among Patients With CABG
0 mg
)
Atorvastatin 80 mg
(n  2,316) p Value
62.7 8.2 0.931
) 1,940 (83.8%) 0.495
) 2,192 (94.6%) 0.319
28.5 4.4 0.166
) 205 (8.9%) 0.477
) 1,319 (57.0%) 0.185
) 403 (17.4%) 0.615
) 1,955 (84.4%) 0.855
) 1,249 (53.9%) 0.080
) 154 (6.6%) 0.975
) 381 (16.5%) 0.121
) 717 (31.0%) 0.633
98 17 0.457
175 24 0.911
154 72 0.743
47 11 0.339
ay.ong
ent G
atin 1
2,338
 8.2
(83.0%
(94.0%
 4.7
(9.5%
(58.9%
(18.0%
(84.2%
(51.4%
(6.6%
(14.8%
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May 20, 2008:1938–43 High-Dose Atorvastatin in Coronary Bypass Patients0-mg group and 371 patients (15.9%) in the 10-mg group
nderwent repeat coronary revascularization, either with
ABG or percutaneous coronary intervention, resulting in a
0% relative risk reduction and a 4.6% absolute reduction
HR 0.70, 95% CI 0.60 to 0.82, p  0.0001). The Kaplan-
eier curves for this outcome are shown in Figure 3. The
ombined end point of a major cardiovascular event or
oronary revascularization occurred in 417 patients (18.0%)
n the 80-mg group compared with 566 patients (24.2%) in
he 10-mg group, a 28% relative risk reduction and a 6.2%
bsolute reduction (HR 0.72, 95% CI 0.64 to 0.82, p 
.0001), as shown in Figure 4. The number of CABG
atients needed to treat with 80 mg compared with 10 mg
ver the 4.9 years of follow-up to prevent a major cardio-
Figure 2 Kaplan-Meier Curves for the Primary
End Point Among Patients With Prior CABG
Abbreviations as in Figure 1.
vents During Follow-Up in Patients With and Without Prior CABG
Table 3 Events During Follow-Up in Patients With and Without
Event Type
Prior CABG
(n  4,654)
Major cardiovascular event 529 (11.4%)
Nonfatal MI 281 (6.0%)
Resuscitated cardiac arrest 30 (0.6%)
Stroke 153 (3.3%)
Cardiovascular death 162 (3.5%)
CHD death 136 (2.9%)
Noncardiovascular death 147 (3.2%)
Death 309 (6.6%)
Major cardiovascular event or death 651 (14.0%)
CHD death or nonfatal MI 391 (8.4%)
First cardiovascular event 1,500 (32.2%)
First coronary event 1,093 (23.5%)
Major coronary event 404 (8.7%)
Heart failure hospital stay 186 (4.0%)
Stroke/transient ischemic attack 255 (5.5%)
Transient ischemic attack 110 (2.4%)
Peripheral vascular disease 357 (7.7%)
ABG  coronary artery bypass graft surgery; CHD  coronary heart disease; CI  confidence intascular event or coronary revascularization is 16. The
rimary and secondary end-point rates for the 80- and
0-mg groups are listed in Table 4.
afety. In the cohort with CABG at baseline, discontinu-
tions from therapy due to treatment-related adverse events
uring the 4.9 years of follow-up occurred in 87 patients
3.8%) in the atorvastatin 80-mg group and in 62 patients
2.7%) in the atorvastatin 10-mg group (p  0.04).
reatment-related myalgias were reported in 1.3% of pa-
ients in both groups, and no post-CABG patient experi-
nced an elevation of creatinine phosphokinase 10  the
pper limit of normal on 2 consecutive measurements.
Figure 3 Kaplan-Meier Curves for Coronary
Revascularization Among Patients With Prior CABG
Revascularization was either repeat CABG or percutaneous coronary interven-
tion, in the 80- and 10-mg atorvastatin groups among patients with prior CABG
at baseline. Abbreviations as in Figure 1.
CABG
Prior CABG
 5,347)
Prior/No Prior
Hazard Ratio (95% CI) p Value
53 (8.5%) 1.38 (1.22–1.56) 0.0001
70 (5.0%) 1.22 (1.04–1.45) 0.0181
21 (0.4%) 1.67 (0.96–2.92) 0.0712
19 (2.2%) 1.51 (1.19–1.92) 0.0007
19 (2.2%) 1.59 (1.25–2.01) 0.0001
92 (1.7%) 1.72 (1.32–2.24) 0.0001
38 (2.6%) 1.26 (1.00–1.59) 0.0485
57 (4.8%) 1.41 (1.20–1.67) 0.0001
85 (10.9%) 1.32 (1.18–1.47) 0.0001
44 (6.4%) 1.33 (1.15–1.54) 0.0001
82 (29.6%) 1.11 (1.04–1.19) 0.0033
11 (24.5%) 0.95 (0.88–1.03) 0.2510
45 (6.5%) 1.36 (1.18–1.57) 0.0001
00 (1.9%) 2.19 (1.72–2.79) 0.0001
93 (3.6%) 1.55 (1.29–1.87) 0.0001
87 (1.6%) 1.47 (1.11–1.95) 0.0069
00 (3.7%) 2.13 (1.79–2.53) 0.0001
I  myocardial infarction.Prior
No
(n
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High-Dose Atorvastatin in Coronary Bypass Patients May 20, 2008:1938–43levated alanine aminotransferase or aspartate aminotrans-
erase 3  the upper limit of normal on consecutive
easurements occurred in 1.1% of patients in the 80-mg
roup and 0.3% of those in the 10-mg group (p  0.0003).
iscussion
atients with previous CABG who had their LDL-cholesterol
owered to approximately 80 mg/dl with atorvastatin 80 mg
ad a significantly better outcome than those with LDL-
holesterol lowered to approximately 100 mg/dl with 10 mg of
torvastatin. Compared with the less-aggressively treated pa-
ients, those in the atorvastatin 80-mg group experienced a
Figure 4 Kaplan-Meier Curves for a Combination of the
Primary End Point or for Coronary Revascularization
Abbreviations as in Figure 1.
vents During Follow-Up in CABG Patients in the 10- and 80-mg Gr
Table 4 Events During Follow-Up in CABG Patients in the 10- a
Event Type
Atorvastatin 10 mg
(n  2,338)
Major cardiovascular event 305 (13.0%)
Nonfatal MI 167 (7.1%)
Resuscitated cardiac arrest 16 (0.7%)
Stroke 84 (3.6%)
Cardiovascular death 93 (4.0%)
CHD death 80 (3.4%)
Noncardiovascular death 62 (2.7%)
Death 155 (6.6%)
Major cardiovascular event or death 355 (15.2%)
CHD death or nonfatal MI 231 (9.9%)
First cardiovascular event 836 (35.8%)
First coronary event 626 (26.8%)
Major coronary event 237 (10.1%)
Heart failure hospital stay 108 (4.6%)
Stroke/transient ischemic attack 145 (6.2%)
Peripheral vascular disease 179 (7.7%)
Transient ischemic attack 66 (2.8%)
First repeat revascularization during follow-up 371 (15.9%)bbreviations as in Table 3.7% reduction in major cardiovascular events and a 30%
eduction in repeat coronary revascularization (either CABG
r percutaneous coronary intervention) during a mean
ollow-up of 4.9 years. The number needed to treat with 80 mg
ompared with 10 mg to prevent 1 of these events was 16.
revious studies. The only large randomized trial of
tatins specifically designed to study patients after CABG
as the Post-CABG trial (8,9), which randomized 1,351
atients with patent venous bypass grafts to 40 or 2.5
g/day of lovastatin, such that LDL-cholesterol levels
uring follow-up ranged from 93 to 97 mg/dl in the
igher-dose group and 132 to 136 mg/dl in the lower-dose
roup. After 4.3 years, graft deterioration was less common
n the aggressively treated group (8), and during subsequent
ollow-up the event rate was also lower (9).
The results of the Post-CABG trial and the results of the
ABG patients in TNT are complementary. Both report
hat more aggressive LDL-cholesterol–lowering is associ-
ted with better outcomes, and TNT extends the benefit to
DL-cholesterol levels in the range of 80 mg/dl. The
ost-CABG trial provides anatomic evidence of reduced
rogression of SVG disease, whereas TNT documents event
eduction for most cardiovascular end points.
tudy limitations. This study has several limitations.
nalysis of CABG patients was not pre-specified in the
tudy protocol. Thus, important prognostic information
elated to CABG, such as number and type of bypass grafts,
umber of diseased vessels, preoperative symptoms, and left
entricular function, is not available.
All patients were treated with a statin so that no com-
arator placebo group is available. However, on the basis of
revious studies in different populations, atorvastatin 10 mg
educed events by approximately one-third (12,13). The
-mg Group
Atorvastatin 80 mg
(n  2,316) Hazard Ratio (95% CI) p Value
224 (9.7%) 0.73 (0.62–0.87) 0.0004
114 (4.9%) 0.68 (0.54–0.86) 0.0015
14 (0.6%) 0.88 (0.43–1.81) 0.7332
69 (3.0%) 0.83 (0.60–1.14) 0.2463
69 (3.0%) 0.75 (0.55–1.02) 0.0667
56 (2.4%) 0.70 (0.50–0.99) 0.0436
85 (3.7%) 1.39 (1.00–1.93) 0.0493
154 (6.6%) 1.00 (0.80–1.25) 0.9771
296 (12.8%) 0.83 (0.71–0.97) 0.0184
160 (6.9%) 0.69 (0.56–0.84) 0.0003
664 (28.7%) 0.77 (0.69–0.85) 0.0001
467 (20.2%) 0.73 (0.65–0.82) 0.0001
167 (7.2%) 0.70 (0.58–0.86) 0.0005
78 (3.4%) 0.72 (0.54–0.97) 0.0289
110 (4.7%) 0.76 (0.59–0.98) 0.0308
178 (7.7%) 1.00 (0.82–1.24) 0.9677
44 (1.9%) 0.67 (0.46–0.98) 0.0379
262 (11.3%) 0.70 (0.60–0.82) 0.0001oup
nd 80
r
l
o
c
b
w
S
i
o
r
A

1
t
1
8
d
l
g
i
c
c
i
(
L
t
d
w
C
I
m
r
B
t
m
r
l
R
R
H
E
R
1
1
1
1
1
1
1943JACC Vol. 51, No. 20, 2008 Shah et al.
May 20, 2008:1938–43 High-Dose Atorvastatin in Coronary Bypass Patientsesults of this analysis indicate that the 80-mg dose and
owering LDL-cholesterol to approximately 80 mg/dl instead
f 100 mg/dl provides substantial additional event reduction.
The TNT patient population was overwhelmingly Cau-
asian and male, with LDL-cholesterol levels off treatment
etween 130 and 250 mg/dl. Whether similar benefits
ould be seen in different types of patients is uncertain.
afety. Atorvastatin 80 mg was well tolerated in TNT, both
n CABG patients and in the overall study population. A total
f 18,696 patients have been treated with atorvastatin 80 mg in
andomized clinical trials, most for 4 to 5 years (4–6,12–15).
cross these trials, the incidence of hepatic enzyme elevation
3  the upper limit of normal on repeat measurements was
.43%, and only 4 patients had creatine kinase levels 10 
he upper limit of normal on repeat measurements.
Both in CABG patients and in the entire TNT cohort of
0,001 patients, total mortality did not differ between the
0- and 10-mg groups. This net balance was the result of a
ecrease in CHD death and an increase in noncardiovascu-
ar death in the 80-mg group compared with the 10-mg
roup, with both differences of borderline statistical signif-
cance. The increase in noncardiovascular mortality was not
oncentrated in any diagnostic category and thus might be a
hance finding. Noncardiovascular mortality was identical
n the 80-mg atorvastatin arms of TNT and IDEAL
Incremental Decrease in End Points Through Aggressive
ipid Lowering trial) (3.2%); noncardiovascular mortality in
he simvastatin arm of IDEAL was 3.5%, a finding that
oes not substantiate an increased noncardiovascular risk
ith high-dose atorvastatin (5).
onclusions
n conclusion, aggressive lipid-lowering with atorvastatin 80
g decreases major cardiovascular events and the need for
epeat revascularization in patients with previous CABG.
ecause this is an especially high-risk population that tends
o be undertreated with lipid-lowering therapy, this treat-
ent should be the new standard of care, with the goal of
educing cardiovascular morbidity and mortality and pro-
onging bypass graft patency.
eprint requests and correspondence to: Dr. David D. Waters,
oom 5G1, Division of Cardiology, San Francisco General
ospital, 1001 Potrero Avenue, San Francisco, California 94110.
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